Ocular Therapeutix will unveil topline results from SOL-1, its phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related...

CorMedix Therapeutics will spend mid‑March on the investor circuit, hosting fireside chats at Leerink Partners and Citizens Life Sciences...

Orion reported a step-change 2025, with net sales up 22.5% to €1.89 billion and operating profit up 51.6% to...

Ipsen reported 2025 sales of €3.68 billion, up 10.9% at constant exchange rates, with core operating income rising 16.7%...

Iovance Biotherapeutics will host its fourth quarter and full-year 2025 results call and webcast on February 24, 2026, at...

Ascendis Pharma closed 2025 with a sharp inflection in rare endocrine commercialization, reporting €684 million in product revenue for...

Psyence Biomedical has settled a shareholder dispute with Kaos Capital, agreeing to pay US$1.5 million, waive a prior C$75,000...

Veru plans to initiate a Phase 2b “Plateau” study this quarter testing enobosarm, an oral selective androgen receptor modulator,...

AscellaHealth has expanded its international leadership, elevating Gillian Molloy to general manager of international operations and appointing Alexis Moss...

Avicanna has closed a non-brokered private placement totaling C$1.55 million, issuing 7,750,001 units at C$0.20 each. Each unit comprises...